The FDA-approved prescribing information does not list autoimmune diseases as contraindications, and clinical practice guidelines from the American Diabetes Association do not restrict GLP-1 receptor agonist use in patients with autoimmune disorders
Purity testing High-performance liquid chromatography, or HPLC, is commonly used to evaluate peptide purity
Referral to clinical genetics or endocrinology may be appropriate for individuals with concerning family histories to guide treatment decisions
3 Model based estimates are based on an analysis of covariance (or logistic regression for the 5%, 10%, 15% or 20% achievement endpoints) including treatment as a factor and baseline value as a covariate
Providers who refuse to prescribe non-approved peptides arent being difficult, theyre keeping you safe and legal
Preclinical evidence is encouraging but preliminary